Progress research on pharmaceutical care of antiviral drugs for patients with corona virus disease 2019 (COVID-19)
Drugs and Clinic
; 35(4):614-619, 2020.
Article
in Chinese
| GIM | ID: covidwho-1374634
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
To improve the rationality and safety of anti-novel coronavirus drugs in patients with corona Virus disease 2019 (COVID-19), especially those with underlying diseases. Based on antiviral drugs mentioned in "COVID-19 Treatment Plan (Trial Version 7)", the clinical pharmacokinetic characteristics, drug interaction and adverse reaction information of these antiviral drugs were summarized by consulting the literature, collecting the information from the antiviral drugs instructions and the information from MCDEX rational drug use system. And the reasonable suggestions for drug monitoring were summarized and put forward. From the perspective of pharmacokinetics and drug interaction, the monitoring of antiviral drugs and combined drugs in patients with COVID-19 should be strengthened, which will be helpful for safe and rational use of these drugs.
Full text:
Available
Collection:
Databases of international organizations
Database:
GIM
Language:
Chinese
Journal:
Drugs and Clinic
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS